The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote competition in health care and support lower prescription drug costs. Among other things, the agencies will seek public input on the impact of private equity and corporate control in health care to identify areas for future regulation and enforcement; improve information sharing to better identify anticompetitive “rollups” that evade antitrust scrutiny; and appoint an HHS chief competition officer and health care chief counsels at DOJ and FTC. 

In addition, the Centers for Medicare & Medicaid Services today released ownership data for Federally Qualified Health Centers and Rural Health Clinics and plans to seek public input early next year to strengthen data and transparency in the Medicare Advantage market, the Administration said. The Department of Commerce and HHS also proposed a framework to promote access to taxpayer-funded inventions, including medical treatments.

Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…